Purchase of Own Shares

Summary by AI BETAClose X

AdvancedAdvT Limited announced the purchase of an additional 22,500 ordinary shares between September 21st and September 25th, 2026, as part of its ongoing share buyback program. These shares, acquired at prices ranging from 174.589p to 175.000p, will be held in treasury. Cumulatively, the company has repurchased 6,211,453 shares since March 4th, 2026. Following these transactions, the total number of voting shares outstanding is now 130,914,353.

Disclaimer*

AdvancedAdvT Limited
28 September 2026
 

This announcement contains inside information
for the purposes of UK Market Abuse Regulation.

 

28 September 2026

AdvancedAdvT Limited

Purchase of Own Shares

AdvancedAdvT Limited (AIM: ADVT, “AdvT”, the “Group”, the “Company”), the international software solutions provider for the business solutions, healthcare compliance, and human capital management sectors, announces that further to the confirmation of its intention to renew its share buyback programme, as set out in its announcement on 16 September 2026, in the period from 21 September 2026 up to and including 25 September 2026, it purchased a further 22,500 of its ordinary shares of no par value in the capital of the Company (“Ordinary Shares”). The Ordinary Shares purchased will be held in treasury.

 

Following this purchase, the cumulative number of Ordinary Shares purchased under the Company’s buyback programmes since 4 March 2026 is 6,211,453.

 

Aggregated information

 

Date of purchase

Number of Ordinary Shares purchased

Highest price paid per Ordinary Share

Lowest price paid per Ordinary Share

Volume Weighted price paid per Ordinary Share

21 September 2026

22,500

175.000p

174.589p

174.817p

 

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation) (which forms part of domestic UK law pursuant to the European Union (Withdrawal) Act 2018), a detailed breakdown of individual trades is available below:

 

Date of purchase

Number of Ordinary Shares purchased

Transaction price

Time of transaction

Trading venue

 21 September 2026

10,000

174.589p

12:07

AIMX

 21 September 2026

12,500

175.000p

13:41

AIMX

 

Total voting rights

 

Following the purchase, the Company's total issued share capital will consist of 137,125,806 Ordinary Shares each carrying one voting right, of which 6,211,453 Ordinary Shares are held in treasury. Therefore, the total number of Ordinary Shares carrying voting rights will be 130,914,353. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The person responsible for arranging the release of this Announcement
on behalf of the Company is Gavin Hugill, Chief Financial Officer.

 

Enquiries:

AdvancedAdvT Limited

 

Vin Murria, Chairperson

Gavin Hugill, Chief Financial Officer

 

 

 

Singer Capital Markets (Nominated Adviser and Broker)

Tel: 020 7496 3000

James Moat / James Fischer

 

 

 

KK Advisory (Investor Relations)

Tel: 020 7039 1901

Kam Bansil 

 

 

Note to Editors

AdvancedAdvT Limited (AdvT) provides software solutions and platforms across two business transformational areas: business solutions & healthcare compliance, and human capital management.

AdvT is an agent for change. The Group enables the delivery of Artificial Intelligence ("AI"), data analytics and business intelligence, all of which are key future drivers for growth in those sectors where long term digitisation trends are set to transform the workplace for professionals. 

AdvT is developing both organically and through acquisitions, by expanding its presence across adjacent markets, geographical boundaries and digital sectors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UK 100

Latest directors dealings